The latest price target for Hims & Hers Health (NYSE:HIMS) was reported by Morgan Stanley on December 17, 2024. The analyst firm set a price target for $42.00 expecting HIMS to rise to within 12 months (a possible 59.21% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Hims & Hers Health (NYSE:HIMS) was provided by Morgan Stanley, and Hims & Hers Health initiated their overweight rating.

The last upgrade for Hims & Hers Health Inc happened on February 9, 2023 when Jefferies raised their price target to $11. Jefferies previously had a hold for Hims & Hers Health Inc.

The last downgrade for Hims & Hers Health Inc happened on November 14, 2024 when B of A Securities changed their price target from $32 to $18 for Hims & Hers Health Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hims & Hers Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hims & Hers Health was filed on December 17, 2024 so you should expect the next rating to be made available sometime around December 17, 2025.

While ratings are subjective and will change, the latest Hims & Hers Health (HIMS) rating was a initiated with a price target of $0.00 to $42.00. The current price Hims & Hers Health (HIMS) is trading at is $26.38, which is within the analyst’s predicted range.